製品番号: HY-B1350

フシジン酸

(別名: Fusidic acid; Fusidate; SQ-16603)

2 Cited Publications

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Fusidic acid (Fusidate) a bacteriostatic antibiotic produced from the Fusidium coccineum fungus, belongs to the class of steroids. Fusidic acid has no corticosteroid effects. Fusidic acid inhibits the growth of bacteria by preventing the release of translation elongation factor G (EF-G) from the ribosome. Fusidic acid holds promise for research in anticancer and anti-infective applications..

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.79%
CAS 番号: 6990-06-3
分子式: C₃₁H₄₈O₆
分子量:516.71

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Fusidic acid 構造式

CAS 番号: 6990-06-3

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (2)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

Bacterial^[1]^[2]^[3]

Antibiotic アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	>194 μM Compound: 1	Cytotoxicity against CHO assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against CHO assessed as cell viability after 48 hrs by MTT assay	10.1039/C5MD00343A
CHO	IC₅₀	>194 μM Compound: Fusidic acid	Cytotoxicity against CHO cells Cytotoxicity against CHO cells	[PMID: 28012840]
CHO	IC₅₀	194 μM Compound: 1	Cytotoxicity against CHO cells by MTT assay Cytotoxicity against CHO cells by MTT assay	[PMID: 30108825]
CHO-K1	IC₅₀	>194 μM Compound: 1	Cytotoxicity against CHOK1 cells assessed as reduction in cell viability Cytotoxicity against CHOK1 cells assessed as reduction in cell viability	[PMID: 32362386]
HEK293	CC₅₀	>32 μg/mL Compound: FA	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
HeLa	IC₅₀	>100 μM Compound: FA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
MKN-45	IC₅₀	>100 μM Compound: FA	Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
RAW264.7	IC₅₀	61.26 μM Compound: FA	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37544187]
Sf21	IC₅₀	11.5 μM Compound: Fusidic acid	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	17.4 μM Compound: Fusidic acid	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
U-87MG ATCC	IC₅₀	>100 μM Compound: FA	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30445262]
Vero	IC₅₀	105.8 μg/mL Compound: Fusidic acid	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 8988597]

体外実験

Fusidic acid (100-200 μM, 72 h) primarily inhibits the proliferation of breast cancer (MCF-7, MDA-MB-231), thyroid cancer (8505C, TPC1), and cervical cancer (Caski, HeLa) cells through cell cycle arrest rather than apoptosis^[3].
Fusidic acid (0.01-100 × MIC, 24 h) exhibits stable intracellular antibacterial activity against methicillin-sensitive Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in THP-1 cells, with potency comparable to Clindamycin (HY-B1455) and Linezolid (HY-10394). MIC at pH 7.4 was 0.25 mg/L, whereas MIC at pH 5.5 decreased to 0.01 mg/L^[4].
Fusidic acid (125 mg/L, 30 min) demonstrates enhanced antibacterial activity against methicillin-sensitive Staphylococcus aureus and significantly increased intracellular accumulation under acidic conditions (pH 5.5)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[3]

Cell Line:

MCF-7, MDA-MB-231 (breast cancer); 8505C, TPC1 (thyroid cancer); Caski, HeLa (cervical cancer)
Concentration:

10 μM, 100 μM, 200 μM
Incubation Time:

72 hours
Result:

Inhibited cell proliferation in a dose-dependent manner:
Breast cancer cells (MCF-7: 100 μM, 28%; MDA-MB-231: 100 μM, 32%)
Thyroid cancer cells (8505C: 200 μM, 43%; TPC1: 100 μM, 45%)
Cervical cancer cells (Caski: 200 μM, 29%; HeLa: 200 μM, 38%)

Cell Cycle Analysis^[3]

Cell Line:

MCF-7, MDA-MB-231 (breast cancer); 8505C, TPC1 (thyroid cancer); Caski, HeLa (cervical cancer)
Concentration:

100 μM, 200 μM
Incubation Time:

72 hours
Result:

Induced different phases of cell cycle arrest depending on cell type:
Breast cancer (MCF-7, MDA-MB-231): G0/G1 phase arrest (MCF-7: 200 μM, 42%; MDA-MB-231: 200 μM, 16%).
Thyroid cancer (8505C, TPC1): S phase arrest (8505C: 200 μM, 12%; TPC1: 200 μM, 7%).
Cervical cancer: Caski: G0/G1 increase 11%; HeLa: G2/M increase 15%.

体内実験

Fusidic acid (1 mg/mL, applied topically as a gel, 20 μL per mouse, once daily for 5 days) effectively reduced Candida albicans infection in the Cyclophosphamide (HY-17420)-induced immunosuppressed vaginal candidiasis mouse model and exhibited synergistic antifungal activity when combined with Fluconazole (HY-B0101)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Cyclophosphamide (HY-17420)-induced immunosuppressed vaginal candidiasis Balb/c mouse model^[5]
Dosage:

1 mg/mL
Administration:

Vaginal gel application (VGA), 20 μL per mouse, once daily for 5 days
Result:

Significantly reduced Candida albicans CFU in vaginal lavage and fungal burden in vaginal tissue.
Caused that antifungal activity was further enhanced when combined with Fluconazole (HY-B0101).
Led to less vaginal tissue damage and inflammation compared to control.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 6990-06-3
性状 Solid
分子量 516.71
分子式 C₃₁H₄₈O₆
Color White to off-white
SMILES

C[C@@H]([C@]1([H])CC[C@]([C@@](C[C@@H]/2OC(C)=O)3C)4C)[C@H](O)CC[C@]1(C)[C@]4([H])[C@H](O)C[C@@]3([H])C2=C(C(O)=O)/CC/C=C(C)\C
別名

Fusidic acid; Fusidate; SQ-16603
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Microorganisms
Fusidium
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

TP53RK Drives the Progression of Chronic Kidney Disease by Phosphorylating Birc5. [Abstract]

2023 Sep;10(25):e2301753. PMID: 37382161
Cell Rep Med

Profiling the metabolome of uterine fluid for early detection of ovarian cancer. [Abstract]

2023 Jun 20;4(6):101061. PMID: 37267943

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (193.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9353 mL

9.6766 mL

19.3532 mL

5 mM

0.3871 mL

1.9353 mL

3.8706 mL

10 mM

0.1935 mL

0.9677 mL

1.9353 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (285 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Curbete MM, et al. A Critical Review of the Properties of Fusidic Acid and Analytical Methods for Its Determination. Crit Rev Anal Chem. 2016;46(4):352-360. [Content Brief]

[2]. Payne AJ, et al. Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice. Parasitol Res. 2013;112(11):3859-3863. [Content Brief]

[3]. Kim JY, et al. Growth inhibition by fusidic acid in cervical, thyroid, and breast carcinoma cell lines. Obstet Gynecol Sci. 2023 Mar;66(2):100-106. [Content Brief]

[4]. Lemaire S, et al. Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin. Clin Infect Dis. 2011 Jun;52 Suppl 7:S493-503. [Content Brief]

[5]. Gomaa SE, et al. The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model. BMC Microbiol. 2024 Feb 10;24(1):54. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9353 mL	9.6766 mL	19.3532 mL	48.3830 mL
	5 mM	0.3871 mL	1.9353 mL	3.8706 mL	9.6766 mL
	10 mM	0.1935 mL	0.9677 mL	1.9353 mL	4.8383 mL
	15 mM	0.1290 mL	0.6451 mL	1.2902 mL	3.2255 mL
	20 mM	0.0968 mL	0.4838 mL	0.9677 mL	2.4192 mL
	25 mM	0.0774 mL	0.3871 mL	0.7741 mL	1.9353 mL
	30 mM	0.0645 mL	0.3226 mL	0.6451 mL	1.6128 mL
	40 mM	0.0484 mL	0.2419 mL	0.4838 mL	1.2096 mL
	50 mM	0.0387 mL	0.1935 mL	0.3871 mL	0.9677 mL
	60 mM	0.0323 mL	0.1613 mL	0.3226 mL	0.8064 mL
	80 mM	0.0242 mL	0.1210 mL	0.2419 mL	0.6048 mL
	100 mM	0.0194 mL	0.0968 mL	0.1935 mL	0.4838 mL

Keywords

Fusidic acid

2 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

フシジン酸

Lipid Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

Terpenoids Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Breast Cancer Compound Library

Microbial Metabolite Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Fatty Acids Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

MedChemExpress（MCE）の使用を引用している文献 Fusidic acid

Antibiotic アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (2)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Fusidic acid 関連分類

HY-B1350 関連分類